|
End-of-day quote
Dhaka S.E.
2026-08-18
|
5-day change | 1st Jan Change | ||
| 776.90 BDT | -0.49% |
|
-2.49% | +9.73% |
Company Valuation: Ambee Pharmaceuticals Plc
Data adjusted to current consolidation scope
| Fiscal Period: June | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 1,154 | 985.2 | 1,260 | 1,318 | 1,829 | 1,960 |
| Change | - | -14.6% | 27.92% | 4.57% | 38.81% | 7.12% |
| Enterprise Value (EV) 1 | 1,370 | 1,210 | 1,588 | 1,682 | 2,274 | 2,466 |
| Change | - | -11.7% | 31.26% | 5.89% | 35.21% | 8.44% |
| P/E | 317x | -75.7x | 156x | 145x | 189x | 369x |
| PBR | 19.9x | 22x | 23.9x | 56.5x | 62.2x | 60.6x |
| PEG | - | 0x | -1x | 11.3x | 28.96x | -8.2x |
| Capitalization / Revenue | 4.04x | 9.95x | 6.96x | 6.65x | 8.34x | 8.5x |
| EV / Revenue | 4.8x | 12.2x | 8.77x | 8.49x | 10.4x | 10.7x |
| EV / EBITDA | 75.6x | -724x | 80.9x | 83.4x | 125x | 198x |
| EV / EBIT | 119x | -166x | 107x | 128x | 183x | 334x |
| EV / FCF | 217x | -489x | -15.2x | 1,497x | -29.7x | -5.1x |
| FCF Yield | 0.46% | -0.2% | -6.6% | 0.07% | -3.36% | -19.6% |
| Dividend per Share 2 | 1.5 | - | 1 | 1.5 | 1 | 1 |
| Rate of return | 0.31% | - | 0.19% | 0.27% | 0.13% | 0.12% |
| EPS 2 | 1.515 | -5.421 | 3.358 | 3.788 | 4.035 | 2.212 |
| Distribution rate | 99% | - | 29.8% | 39.6% | 24.8% | 45.2% |
| Net sales 1 | 285.3 | 98.98 | 181 | 198.1 | 219.3 | 230.6 |
| EBITDA 1 | 18.12 | -1.672 | 19.64 | 20.16 | 18.26 | 12.46 |
| EBIT 1 | 11.5 | -7.282 | 14.86 | 13.17 | 12.41 | 7.388 |
| Net income 1 | 3.637 | -13.01 | 8.059 | 9.09 | 9.683 | 5.309 |
| Net Debt 1 | 216.6 | 224.8 | 328 | 363.9 | 444.7 | 506.3 |
| Reference price 2 | 480.70 | 410.50 | 525.10 | 549.10 | 762.20 | 816.50 |
| Nbr of stocks (in thousands) | 2,400 | 2,400 | 2,400 | 2,400 | 2,400 | 2,400 |
| Announcement Date | 6/27/21 | 12/14/21 | 12/10/22 | 12/7/23 | 12/5/24 | 11/26/25 |
1BDT in Million2BDT
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 15.2M | |
| 34.6x | 6.48x | 22.46x | 0.91% | 46.96B | |
| 18.37x | 2.19x | 9.9x | 1.41% | 39.63B | |
| 27.86x | 3.39x | 17.55x | 0.91% | 12.07B | |
| 26.75x | 3.83x | 15.86x | 0.61% | 11.61B | |
| 18.73x | 3.33x | 11.58x | 3.85% | 9.11B | |
| 9.06x | 2.09x | 5.45x | 4.44% | 7.47B | |
| 15.9x | 2.07x | 6.73x | 3.21% | 7.18B | |
| 28.04x | 3.66x | 17.01x | 0.17% | 6.79B | |
| Average | 22.41x | 3.38x | 13.32x | 1.94% | 15.65B | |
| Weighted average by Cap. | 25.15x | 3.99x | 15.29x | 1.48% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- AMBEEPHA Stock
- Valuation Ambee Pharmaceuticals Plc
Select your edition
All financial news and data tailored to specific country editions
